Prompted by our observations and those of others, the av?3 integrin is a current therapeutic anti-resorptive target for diseases such as osteoporosis and inflammatory osteolysis. The purpose of this grant, from its inception, has been to expand the potential of therapeutically targeting the integrin by characterizing its associated molecules and the bone-degrading signals they transmit. The success of this exercise is underscored by the fact that in addition to those inhibiting av?3, drugs targeting signaling molecules, such as c-Src and Syk, which are effectors of the integrin, in OCs, are in clinical trial for osteolytic diseases. We have, in the past funding period, fulfilled our specific aims. While our efforts continue to define the mechanisms by which av?3 regulates the OC, particularly in the context of derivative signals which organize its cytoskeleton, our current attention turns to the integrin, itself. We address the mechanisms by which the integrin assumes an activated conformation which permits it to recognize ligand and transmit its bone-resorptive signals. Our findings and those of others, indicate M-CSF plays a central role in this regard. We have established that av?3 and M-CSF collaborate in organizing the OC cytoskeleton. Our data indicate, however, that the principal means by which M-CSF exerts its cytoskeletal effect is to prompt its receptor c-Fms to transmit intracellular signals to the cytoplasmic domain of the ?3 integrin subunit. These signals, in turn, transit the integrin from its default, resting state, to its activated conformation, permitting ligand recognition and cytoskeleton-organizing events. Our findings also suggest that talin activates OC av?3 and the signals derived thereof, by interacting with specific residues in the ?3 integrin cytoplasmic domain. We hypothesize, therefore that 1) M-CSF, liganding its receptor, c-Fms, transmits intracellular signals which activate the av?3 integrin in OCs;2) talin and its recognition sequences in the ?3 cyoplasmic domain mediate M-CSF-induced OC cytoskeletal organization and function and 3) inhibiting av?3 activation, in vivo, diminishes pathological bone resorption.
Our specific aims are therefore to determine 1) the mechanism by which M-CSF, interacting with its receptor c-Fms, transmits intracellular signals which activate the av?3 integrin in OCs;2) the role of talin and its recognition sequences in the ?3 integrin cytoplasmic domain in mediating M-CSF-induced OC cytoskeletal organization and function and 3) the impact of inhibiting av?3 activation, in vivo, on pathological bone resorption.

Public Health Relevance

Most patients at risk for osteoporotic fractures are treated with bisphosphonates, which are increasingly associated with complications such as atypical fractures. The present grant, from its inception, has focused on discovering new therapeutic targets for these patients, specifically addressing molecules, known as integrins, which mediate the attachment of bone resorbing cells to skeletal matrix. The success of our efforts is underscored by the fact that integrin-targeting drugs are in clinical trial for the treatment of osteoporosis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37AR046523-16
Application #
8606174
Study Section
Skeletal Biology Structure and Regeneration Study Section (SBSR)
Program Officer
Sharrock, William J
Project Start
2000-02-01
Project End
2015-01-31
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
16
Fiscal Year
2014
Total Cost
$295,488
Indirect Cost
$101,088
Name
Washington University
Department
Pathology
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Zou, Wei; Croke, Monica; Fukunaga, Tomohiro et al. (2013) Zap70 inhibits Syk-mediated osteoclast function. J Cell Biochem 114:1871-8
Zhu, Tingting; Chappel, Jean C; Hsu, Fong-Fu et al. (2013) Type I phosphotidylinosotol 4-phosphate 5-kinase ? regulates osteoclasts in a bifunctional manner. J Biol Chem 288:5268-77
Zou, Wei; Izawa, Takashi; Zhu, Tingting et al. (2013) Talin1 and Rap1 are critical for osteoclast function. Mol Cell Biol 33:830-44
Craft, Clarissa S; Broekelmann, Thomas J; Zou, Wei et al. (2012) Oophorectomy-induced bone loss is attenuated in MAGP1-deficient mice. J Cell Biochem 113:93-9
DeSelm, Carl J; Miller, Brian C; Zou, Wei et al. (2011) Autophagy proteins regulate the secretory component of osteoclastic bone resorption. Dev Cell 21:966-74
Croke, Monica; Ross, F Patrick; Korhonen, Matti et al. (2011) Rac deletion in osteoclasts causes severe osteopetrosis. J Cell Sci 124:3811-21
Hong, Jung Min; Teitelbaum, Steven L; Kim, Tae-Ho et al. (2011) Calpain-6, a target molecule of glucocorticoids, regulates osteoclastic bone resorption via cytoskeletal organization and microtubule acetylation. J Bone Miner Res 26:657-65
van Meel, Eline; Boonen, Marielle; Zhao, Haibo et al. (2011) Disruption of the Man-6-P targeting pathway in mice impairs osteoclast secretory lysosome biogenesis. Traffic 12:912-24
Zou, Wei; Zhu, Tingting; Craft, Clarissa S et al. (2010) Cytoskeletal dysfunction dominates in DAP12-deficient osteoclasts. J Cell Sci 123:2955-63
Craft, Clarissa S; Zou, Wei; Watkins, Marcus et al. (2010) Microfibril-associated glycoprotein-1, an extracellular matrix regulator of bone remodeling. J Biol Chem 285:23858-67

Showing the most recent 10 out of 15 publications